Nicolas U Gerber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3249457/publications.pdf

Version: 2024-02-01

41	810	623734	526287
papers	citations	14 h-index	27 g-index

42	42	42	1219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
2	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
3	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
4	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007.	1.2	72
5	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
6	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.8	39
7	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
8	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. Cancers, 2020, 12, 611.	3.7	23
9	Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. Journal of Neuro-Oncology, 2011, 102, 459-469.	2.9	22
10	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	2.8	22
11	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
12	Ventricular Catheter Systems with Subcutaneous Reservoirs (Ommaya Reservoirs) in Pediatric Patients with Brain Tumors: Infections and Other Complications. Neuropediatrics, 2015, 46, 401-409.	0.6	17
13	A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. European Journal of Cancer, 2012, 48, 2028-2036.	2.8	16
14	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	2.0	16
15	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
16	Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004. Neuropediatrics, 2018, 49, 314-323.	0.6	14
17	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
18	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13

#	Article	IF	Citations
19	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. Neuro-Oncology Practice, 2017, 4, 29-39.	1.6	12
20	A single supratentorial highâ€grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival. Pediatric Blood and Cancer, 2020, 67, e28384.	1.5	12
21	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. Neuro-Oncology, 2022, 24, 127-137.	1.2	9
22	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. Blood, 2020, 136, 37-38.	1.4	8
23	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastomaâ€"an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	2.0	4
24	Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).. Journal of Clinical Oncology, 2016, 34, 10551-10551.	1.6	4
25	Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.. Journal of Clinical Oncology, 2020, 38, 10501-10501.	1.6	4
26	Educational Attainment and Employment Outcome of Survivors of Pediatric CNS Tumors in Switzerlandâ€"A Report from the Swiss Childhood Cancer Survivor Study. Children, 2022, 9, 411.	1.5	4
27	Natural history of a medulloblastoma: 30Âmonths of wait and see in a child with a cerebellar incidentaloma. Child's Nervous System, 2013, 29, 1207-1210.	1.1	3
28	Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trialâ€"A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.. Journal of Clinical Oncology, 2019, 37, 10001-10001.	1.6	3
29	The first report of pediatric patients with solid tumors treated with venetoclax.. Journal of Clinical Oncology, 2020, 38, 10524-10524.	1.6	3
30	Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes. Journal of Neuro-Oncology, 2022, 157, 307-317.	2.9	3
31	Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial. European Journal of Cancer, 2022, 164, 30-38.	2.8	3
32	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
33	Ommaya reservoir â€œoffâ€dutyâ€•causing major lateâ€onset complications in a child with medulloblastoma. Pediatric Blood and Cancer, 2017, 64, e26384.	1.5	1
34	PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL. Neuro-Oncology, 2020, 22, iii425-iii426.	1.2	1
35	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	1.2	1
36	Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.. Journal of Clinical Oncology, 2022, 40, 10039-10039.	1.6	1

#	Article	IF	Citations
37	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	1.2	0
38	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0
39	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	1.2	0
40	NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) â€“ Finding Evidence by systematic Analyses. Neuro-Oncology, 2022, 24, i130-i131.	1.2	0
41	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0